Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
about
Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studiesEzetimibe for primary hypercholesterolemiaEzetimibe for primary hypercholesterolemiaThe evidence base for fat guidelines: a balanced dietRisk factor thresholds: their existence under scrutinyPartial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive casesMetabolic complications of androgen deprivation therapy for prostate cancerGenetic determinants of serum lipid levels in Chinese subjects: a population-based study in Shanghai, ChinaCocoa, chocolate, and cardiovascular diseaseThe Effects of Chunghyul-Dan (A Korean Medicine Herbal Complex) on Cardiovascular and Cerebrovascular Diseases: A Narrative ReviewPCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabLipids in liver transplant recipientsStatins: Cholesterol guidelines and Indian perspectiveZebrafish Models for Dyslipidemia and Atherosclerosis ResearchNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilMultivariate risk assessment and risk score cards in hypertensionEffects of exercise and diet on chronic diseaseFactors Associated with Lipid Goal Attainment among Patients with Deployed Drug Eluting StentImplications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic targetEchocardiographic assessment of maximum and minimum left atrial volumes: a population-based study of middle-aged and older subjects without apparent cardiovascular disease.Hepatic lipase as a focal point for the development and treatment of coronary artery disease.Cholesterol lowering and coronary artery disease: mechanisms of risk reduction.PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDYPrevalence of dyslipidemia in iran: a systematic review and meta-analysis study.Apheresis technology for prevention and regression of atherosclerosis: an overview.American Diabetes Association indications for statins in diabetes: is there evidence?The clinical challenges of myocardial infarction in the elderly.A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterolCholesterol screening and family history of vascular diseaseRole of Intestinal LXRα in Regulating Post-prandial Lipid Excursion and Diet-Induced Hypercholesterolemia and Hepatic Lipid Accumulation.Oxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study.Coronary atherosclerosis and interventions: pathological sequences and restenosis.Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin.Cholesterol screening and cholesterol lowering treatmentSerum lipid and apolipoprotein distributions in Hong Kong ChineseDrug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial LectureNitric oxide-mediated endothlium-dependent vasodilation is impaired with borderline high-LDL cholesterolCross-sectional relations of lipid concentrations to left ventricular structural attributes.Analysis of sequence variations in low-density lipoprotein receptor gene among Malaysian patients with familial hypercholesterolemia.Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects
P2860
Q22242059-D7475C33-513D-4DAB-9462-16659D508A7CQ24187681-79352FBE-343E-47FD-9106-4B75A14E08E2Q24244704-D6F8C8BA-7633-4F6F-A73C-1AB4115030C3Q24289029-27323301-14D1-4ED1-8960-853FCE3ACA3AQ24527206-7BEE0A48-CB67-499D-A969-6DA10CCBFDE4Q24540405-198020C0-9432-470F-88A8-1A959A6B671AQ24616159-034AEDAA-C090-4678-8A14-D580FF5BD71DQ24634163-A4861155-1BAC-43F2-8263-98AFD87388A0Q24654705-62038EEA-C4AE-4131-B6B7-C0A8D485DF2CQ26747311-4519AD28-DACD-4330-B88B-EBC3905643DDQ26747776-BBBDEEB8-67FE-4099-A61F-92AEB135EB81Q26750468-AFD0B22F-6A12-46DB-B645-8B2B824A8CFDQ26783226-B981501E-7DDA-4546-8EB9-AF3554467B50Q28069803-DC745F94-D3E9-4704-8895-68CC6E71EC39Q28084156-84842778-C019-40ED-A317-A989F08AAE08Q28219606-142157CB-D208-4C9B-9287-1A4EA2A2915EQ28297798-56651C25-3FEA-4FF4-A9C4-75115B0521F0Q28468714-6AEBD606-3654-4017-A57B-BD8B7BD85359Q30370672-63BAC3D2-C331-48E3-AE4A-6658BE891B4BQ30420532-90894E5E-2935-43BE-A0F0-23430809C965Q32056551-A8A0B8A1-AD7D-4DF4-B9EA-5BF68468E321Q33538129-51856078-DD9A-42E3-8407-7EE6A38A07B1Q33588399-477DAA69-CE56-43E7-9DCB-8A9DE6390421Q33600617-CE583DD4-E6BF-4C81-B575-BD84B64BEA53Q33606743-DD134B61-D398-4311-9A14-455501956377Q33610712-47E6BA45-019B-4A10-BD69-B315AC3AF4BCQ33617341-C96D02A7-F887-4D06-8948-BBD32B8805DBQ33623917-9CC1ED86-F4FB-4A4B-AAB0-07B10D4742CCQ33625024-A224B2C1-489B-4EDD-89C8-2AFC3875A3F7Q33650363-1505F709-5772-409F-B34E-3E353095B50AQ33653555-517D6DF9-F40E-4087-8A2E-0AEFEB9BE59CQ33655853-E001CACD-A833-4259-83E3-5A78555CF28EQ33680229-2AA404F3-F0AC-491F-8719-84B3895EECE8Q33691286-D153BE00-6050-4E8B-A7CE-12F6BD792BA9Q33702528-C7B75DF9-0BF4-4855-821F-C9997CDB44D0Q33703000-EFBF2162-EFAF-4CFA-9CD9-302BFA0E1D34Q33713545-2811384C-F8F7-4837-9F22-787A91F9F316Q33835564-EA3928F8-9870-419A-90D1-B36B62EEC139Q33850303-E3740A80-46EA-442E-99F1-733B5E0D0463Q33891495-332A0C34-F597-4AF7-8DD6-8A248B423401
P2860
Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh-hant
name
Is relationship between serum ...... or Intervention Trial (MRFIT).
@en
Is relationship between serum ...... or Intervention Trial (MRFIT).
@nl
type
label
Is relationship between serum ...... or Intervention Trial (MRFIT).
@en
Is relationship between serum ...... or Intervention Trial (MRFIT).
@nl
prefLabel
Is relationship between serum ...... or Intervention Trial (MRFIT).
@en
Is relationship between serum ...... or Intervention Trial (MRFIT).
@nl
P2093
P1476
Is relationship between serum ...... or Intervention Trial (MRFIT).
@en
P2093
D Wentworth
J D Neaton
P304
P356
10.1001/JAMA.1986.03380200061022
P407
P577
1986-11-01T00:00:00Z